President Trump’s Drug Pricing Blueprint
We’re excited to continue our advocacy blog series meant to help you take care when it comes to important arthritis health care and coverage issues. If you are just now tuning into this series, check out our previous blog posts on accumulator adjustment programs and pharmacist gag orders.
This week, read on to learn more about President Trump’s drug pricing blueprint and the different policy areas that the plan addresses.
Why did the Administration decide to release a drug pricing blueprint?
On Friday, May 11 the Administration released its long-awaited plan, “Putting Patients First,” intended to help lower drug prices and reduce out-of-pocket costs for patients. President Trump has spoken at length about the need to tackle prescription drug prices, and the blueprint released last week was an effort to follow through on that promise.
In response to the blueprint, the Arthritis Foundation released a brief statement on social media, expressing cautious optimism, but urging thoughtful development of proposals going forward.
Continue reading TAKE CARE: Advocacy Blog Series
Pharmacy Benefit Manager Gag Orders and Clawbacks
We’re excited to present our second blog in a series meant to help you take care when it comes to important arthritis health care and coverage issues. This week we’ll tell you about a practice some pharmacy benefit managers have been using called clawbacks, which affect the price of medications you pay at the pharmacy counter. Read on to learn more and see how the Arthritis Foundation is addressing the issue.
What are clawbacks?
A person who fills his or her prescription at the pharmacy may pay more for a prescription drug with insurance than if he or she had filled it without insurance. This can occur due to a “clawback,” a term used to describe the difference between the cash cost of a drug (purchasing a drug without insurance) and the copayment required by your health plan. That difference, the clawback, is often passed by the pharmacy back to the pharmacy benefit manager (PBM) as a profit. Unfortunately, this often occurs without the patient ever knowing they could avoid the higher copay by paying without insurance. A provision in the contract between the pharmacist and the PBM, known as a “gag order,” prohibits the pharmacist from disclosing cost information related to payment options.
Continue reading TAKE CARE: Advocacy Blog Series
Accumulator Adjustment Programs
We’re excited to present a new advocacy blog series meant to help you take care when it comes to important arthritis health care and coverage issues. Over the next two months, we’ll post a blog every other week to help patients like you know what access issues we are watching and what you can do about them. This week we’ll tell you about a new policy many pharmacy benefit managers (PBMs) are using called accumulator adjustment programs, which could especially impact people in high deductible health plans. Read on to learn more about these programs and why they are being implemented. Continue reading TAKE CARE: Advocacy Blog Series
Scores of the most passionate and vocal champions of the arthritis community recently descended on the nation’s capital to hone their advocacy skills and share their personal stories with each other and with their members of Congress. Attended by nearly 130 participants from 32 states, the Arthritis Foundation’s new Platinum Ambassadors Assembly was held March 12-13.
Platinum Ambassadors are top grassroots volunteers who complete six annual advocacy assignments and raise at least $1,000 to support the Foundation’s mission to conquer and cure arthritis. Forty-eight of our fifty-one Platinum Ambassadors participated in the first-of-its-kind event, along with 25 Junior Ambassadors, young people ages 13 to 17 who speak out for the estimated 300,000 kids in the U.S. who battle arthritis. Also attending were 30 future advocacy leaders, highly-engaged Arthritis Foundation volunteers who have committed to achieving Platinum Ambassador status in 2018.
Continue reading 2018 Arthritis Platinum Ambassador Assembly Makes a Big Impact
Platinum Ambassador Assembly Social Campaign
Did you know that the first ever Platinum Ambassador Assembly is taking place in Washington, DC this March 12-13? There, our most highly engaged grassroots Ambassadors will gather together to be the voice for arthritis on Capitol Hill.
We’re calling on you to help amplify the voice of our Platinum Ambassador Assembly by participating virtually in our #AdvocateforArthritis social media campaign on Tuesday, March 13. On that day Platinum Ambassador Assembly participants will be on Capitol Hill to meet their elected officials and their staff in person to discuss legislative priorities like reforming burdensome step therapy practices, addressing the pediatric rheumatologist shortage, and even securing funding for research for a cure!
Continue reading Show Us How YOU #AdvocateforArthritis
ADVOCACY COMMITTEE REACHES GOAL!
By Amy Barron, Platinum Ambassador, OH Advocacy Committee
I am privileged to serve as a member of the Arthritis Foundation’s Ohio State Advocacy Committee. Advocacy committees like mine help to chart the course of local and state-wide advocacy action for our arthritis community. Many of our committee members serve as Arthritis Foundation Advocates and Ambassadors, at both the state and federal level.
Continue reading Platinum Ambassador Spotlight: Amy Barron, OHIO
On Wednesday, December 20, Congress passed the Tax Cuts and Jobs Act (TCJA). There were several health-related changes included in the legislation, such as a repeal of the Affordable Care Act’s individual mandate, and changes to the medical expenditure tax deduction. Below we explain the key health provisions that made it into the final law, how it may impact you, and what’s next.
Let’s start with the individual mandate.
Continue reading Answering Your Questions About the New Tax Reform Legislation
In 2016, I was fortunate to attend the Arthritis Foundation Advocacy Summit in Washington D.C. alongside some seasoned advocacy veterans from Denver. I had never met with my legislators or shared my story before, so it was a new experience. It was easy to “catch the bug” for advocacy being surrounded by so many other fellow arthritis patient advocates who want to make a difference for all of us. Raising awareness and fundraising for arthritis has been an integral part of my life for the past several years, but advocacy has become an even greater passion. This year, I achieved the Platinum Ambassador Award and will attend the Arthritis Foundation’s Platinum Ambassador Assembly this March 12-13, 2018.
Continue reading Platinum Ambassador Spotlight—Rebecca Gillett, Colorado
During this season of open enrollment, the Arthritis Foundation is here to help you make an informed decision in selecting the best health coverage for your unique needs. Open enrollment is the time of year when individuals elect health care benefits through their employer, Medicare, Medicaid, or the federal and state health exchanges created through the Affordable Care Act. Open enrollment periods vary based on the type of insurance you have, but generally occur in the late fall.
As part of our commitment, the Arthritis Foundation hosted a webinar last month to provide a general overview of open enrollment and the tools and resources you need to secure the best health care for you and your family. In addition, we hosted our very first Twitter chat on November 9th devoted to this year’s open enrollment. Thousands of you engaged with us on Twitter to #AsktheAF and we rounded up your questions in one location.
Read on to learn more about open enrollment and the questions you asked during the Twitter chat. If you have further questions, the Arthritis Foundation also has licensed clinical social workers available to talk with you about these options or any other questions you may have about your care. Call toll-free at 1-844-571-HELP.
Continue reading #AsktheAF: Open Enrollment Edition!
On Thursday, November 2, the Centers for Medicare and Medicaid Services (CMS) announced they would reverse a policy determining how providers are paid for administering biosimilar drugs under Medicare Part B. A biosimilar is a type of medication that is “similar” to a biologic reference product, approved by the Food and Drug Administration (FDA); biosimilars offer patients the promise of more affordable treatment options available on the market to address their disease.
Over the past twenty-four months, the Arthritis Foundation and other patient organizations have expressed our collective concerns with CMS’s biosimilars reimbursement policy and encouraged them to reverse it. This policy reversal is a crucial access to care victory for the arthritis community since there are two biosimilars on the market to treat arthritis. The regulatory change will foster competition and lower the cost of expensive biologic treatments, while encouraging innovation of new therapies – ultimately creating a robust marketplace of biosimilars. Read on to learn more about this important win for patients.
Continue reading Arthritis Foundation Plays a Role in CMS Biosimilars Policy Reversal